NCT01431170View on ClinicalTrials.gov

Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Congenital Nasolacrimal Duct Obstruction
Interventions
DRUG

Besivance Treatment Group

Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.

DRUG

Polytrim Treatment Group

Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.

Trial Locations (1)

07103

Institute of Ophthalmology and Visual Science, RUTGERS-New Jersey Medical School, Newark

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER

NCT01431170 - Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children | Biotech Hunter | Biotech Hunter